Navigation Links
PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development

Cary, NC (PRWEB) January 22, 2013

Dr. Bruce Rehlaender has been appointed a Principal, Formulation Development at PharmaDirections. He will be based in the Portland, Oregon area and will have proximity to a growing market in early stage drug development. The appointment is a reflection of the invaluable contributions he has made over the past 6 years to the virtual biotech companies served by PharmaDirections.

Dr. Rehlaender joined PharmaDirections in 2007 as the Director, Formulation Development. In that capacity, he led multi-disciplinary teams of product development scientists who developed novel drug products using specialized expertise in biopharmaceutics, pharmacokinetics and formulation development.

There have been many significant achievements in his tenure, but we only have room for a few. Dr. Rehlaender led the development of the tri-layer, sustained release tablet formulations for Orexigen’s Contrave; that NDA was filed in 2010. He led many In-Silico PK Modeling programs that resulted in establishing optimum release patterns for over 12 unique client programs. He is the inventor on 5 patents that were developed for PharmaDirections’ clients was responsible for the formulation development efforts in over 20 unique client programs.

Over his 25 year industrial career, Dr. Rehlaender has developed his expertise in biopharmaceutics and formulation development with special expertise in challenges such as poorly soluble drugs, unstable compounds, and sophisticated controlled release patterns. He has extensive experience in developing parenteral products; oral tablets, capsules, and liquids; nebulizer products; dry powder inhalers; and topicals. His experience covers product processing from bench top to commercial manufacturing where he has developed processes for emulsification, powder milling, steam sterilization; aseptic manufacture; lyophilization; and separation of proteins.

Dr. Rehlaender's analytical expertise is primarily in solids characterization, including differential scanning calorimetry, thermogravimetric analysis, dynamic vapor sorption, powder flow measurement, and particle sizing using laser diffraction, photon correlation spectroscopy; electrozone sensing, and light obscuration.

About PharmaDirections

PharmaDirections is a consulting and project management company with a unique approach to managing preclinical, CMC and regulatory affairs programs. We provide strategic planning then oversee and direct pharmaceutical contract research using our own scientific experts and project managers. We are a comprehensive resource for virtual pharmaceutical and biotech companies who need to stay lean by outsourcing their R&D activities.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
2. NSG Announces New Quartz Micro Flow Channel
3. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
4. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
5. ASAE Foundation Announces Winners of the Innovation Grant Program
6. LATISTA Announces Next-Generation iPad App 2.0 for Construction with Industry Leading Innovations
7. GlycoCheck Announces Partnership in the United States with Vascular Health Sciences
8. Wysebridge Patent Bar Review Announces the Launch of News Blog
9. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
10. BroadData Conferencing Announces Enhanced International Audio Conference Call Capabilities
11. Announces New Tri-Fold Scientific Poster Service
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):